2023 ASCO-GU尿路上皮癌精粹解读  

The interpretation of urothelial carcinoma at the 2023 ASCO-GU

作　　者：鲍一歌 韩苏军[2] 黄海[3] Bao Yige;Han Sujun;Huang Hai(Department of Urology,West China Hospital,Sichuan University,Chengdu 610041,China;Department of Urology,Cancer Hospital,Chinese Academy of Medical Sciences and Pehing Union Medical Cllege,Bejing 100021,China;Department of Urology,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510289,China)

机构地区：[1]四川大学华西医院泌尿外科,成都610041 [2]中国医学科学院肿瘤医院泌尿外科,北京100021 [3]中山大学孙逸仙纪念医院泌尿外科,广州510289

出　　处：《中华泌尿外科杂志》2023年第4期251-254,共4页Chinese Journal of Urology

摘　　要：2023年美国临床肿瘤学会泌尿男生殖系肿瘤研讨会(ASCO-GU)报告多项尿路上皮癌进展。新方案应用于非肌层浸润性膀胱癌(NMIBC)治疗, 为卡介苗抵抗/失败NMIBC提供更多选择。肌层浸润性膀胱癌(MIBC)围手术期治疗中, CheckMate274研究3年随访数据显示纳武利尤单抗辅助治疗组无疾病生存率优势。转移性尿路上皮癌(mUC)方面, IMvigor130研究总生存率(OS)报告发布, 引发mUC一线治疗思考。会议还关注上尿路尿路上皮癌(UTUC)研究。The 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium(ASCO-CU)reported several advancements in the field of urothelial carcinoma.Multiple new treatment options for non-muscle invasive bladder cancer(NMIBC)were introduced,providing more choices for bladder preservation in BCG-resistant/failed NMIBC cases.In muscle invasive bladder cancer(MIBC)perioperative treatment,the updated 3-year follow-up data from the CheckMate 274 study demonstrated a clear advantage in disease-free survival for the nivolumab monotherapy adjuvant treatment group.For metastatic urothelial carcinoma(mUC),the final overall survival(OS)report from the IMvigorl30 study was published,prompting further considerations for future first-line treatment options in mUC.Additionally,the conference highlighted research progress in upper tract urothelial carcinoma(UTUC).

关 键 词：尿路上皮癌 非肌层浸润性膀胱癌 肌层浸润性膀胱癌 肿瘤免疫治疗 ASCO-GU会议 

分 类 号：R737.1[医药卫生—肿瘤]